Novartis announced that it will pay $245 million to resolve civil litigation in the US which accuses it of a ‘pay for delay’ scheme involving generics of its high blood pressure therapy Exforge.

Novartis agrees $245m settlement over Exforge generics delay

December 29, 2022 by Chain Drug Review Novartis announced that it will pay $245 million to resolve civil litigation in the US which accuses it of a ‘pay for delay’ scheme involving generics of its high blood pressure therapy Exforge. Leading Headlines, Pharmacy

NEW YORK — Novartis announced this week that it will pay $245 million to resolve civil litigation in the US which accuses it of a ‘pay for delay’ scheme involving generics of its high blood pressure therapy Exforge. The case is about allegations that Novartis made an agreement in 2011 with Par Pharmaceutical when Exforge